A new drug that slows the pace of Alzheimer’s disease is too expensive for too little benefit to be used on the NHS, the drugs spending watchdog says. Donanemab was hailed as a turning point in the disease last year. But the National Institute of Health and Care Excellence (NICE) said the drug provided only … Read more
Sally Magnusson Sally Magnusson has already written a book about how her family coped with her mother’s dementia There can’t be many people who spend years raging and grieving over the decline of a parent from dementia without wondering if it awaits them too. I’m one. My mother died of this vicious brain condition in … Read more
The first drug shown to slow the destruction of the brain in Alzheimer’s disease will not be available on the NHS after a decision by the medicine’s regulator. The decision on funding lecanemab has caused upset and disappointment from those hoping the drug could help fight a horrible and devastating disease. But the decision is … Read more
Getty Images The first drug to slow the progression of early stage Alzheimer’s won’t be available on the NHS in England because health assessment body NICE says the benefits “are too small to justify the costs”. Lecanemab has been licensed by the UK medicines regulator, the MHRA, which means it can be prescribed privately. In … Read more
Getty Images The European Medicines Agency (EMA) has rejected a licence for an Alzheimer’s treatment which slows cognitive decline. The EMA said the benefits of lecanemab did not counterbalance the risk of serious side effects, especially bleeding and swelling in the brain. The medicines regulator in the UK, the MHRA, is still considering whether to … Read more
John Jennings may have inherited a gene from his mother that could trigger early-onset of the condition. Source link
The long-term hope is that more people will be able to access new treatments at an earlier stage. Source link
Washington: Scientists have found a way to help Alzheimer’s drugs seep inside the brain faster – by temporarily breaching its protective shield. The novel experiment was a first attempt in just three patients. But in spots in the brain where the new technology took aim, it enhanced removal of Alzheimer’s trademark brain-clogging plaque, researchers reported … Read more
A £5m study will begin in January to see how feasible it is to offer these types of tests to patients. Source link
The findings, which had been a mystery for decades, give new ideas for treating the disease. Source link